Drugmakers with losartan still on the market will be allowed to sell the drug if it has below 9.82 parts per million of N-Nitroso-N-methyl-4-aminobutyric acid. NMBA is a known animal carcinogen, and may cause cancer in humans.
The FDA will allow the sale of the drugs until the impurity is eliminated.
Since last summer, there have been a string of recalls related to generic blood pressure medications. Two other likely carcinogenic impurities — N-Nitrosodimethylamine and N-Nitrosodiethylamine — were detected in generic blood pressure drugs irbesartan and valsartan.
The recalls prompted the FDA to warn providers and the public about the possibility of a shortage of generic blood pressure medication.
On March 12 the FDA approved a new generic version of valsartan to ease the shortages triggered by the recalls.
The FDA said it expects companies to be able to manufacture losartan without NMBA and replenish supplies in the U.S. in about six months.
More articles on pharmacy:
Harvard gets $100M infusion for drug research from hedge fund
Purdue Pharma CEO: Bankruptcy is ‘an option’ amid lawsuits
Intermountain CEO Dr. Marc Harrison: How Civica Rx will disrupt the drug industry
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.